Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging

Summary

The degree of thrombus resolution directly indicates the effectiveness of a thrombolytic drug. We investigated the degree of thrombus resolution and factors associated with thrombus resolution after intravenous (IV) recombinant tissue plasminogen activator (rt-PA) using thin-section noncontrast computed tomography (NCT). Thin-section NCTs were performed before and immediately after IV rt-PA infusion in acute stroke patients. The thrombus volume and Hounsfield unit were measured using three-dimensional imaging software. Immediate recanalisation was assessed immediately after IV rt-PA infusion using CT angiography. During a three-year study period, 130 patients were prospectively enrolled. On baseline thin-section NCT, no thrombi were found in 30 patients (23%). Among the 100 patients with confirmed thrombus, the median volume decreased by 20% on the follow-up NCT. The thrombus was completely resolved in 8%. Of note, an increase in thrombus volume was observed in 20 patients. Independent predictors of thrombus resolution were total rt-PA dose, thrombus location in the M2 segment of the middle cerebral artery, and time from baseline to follow-up NCT. Thrombus resolution increased by 9% per each 10-mg increase in rt-PA (p = 0.045). Immediate complete recanalisation was achieved in 12% of patients. Total dose of rt-PA was independently associated with complete recanalisation [odds ratio [OR] 4.52, 95% confidence interval [CI] 1.345–15.184) and good functional outcome at three months (modified Rankin scale score <3, OR 2.34, 95% CI 1.104–4.962). In conclusion, rt-PA dose was associated with the degree of thrombus resolution, immediate complete recanalisation, and good outcome at three months. CT-based thrombus imaging may be helpful in determining thrombolysis effectiveness.

Keywords

Computed tomography - thrombus - thrombolytic therapy - cerebrovascular disease

• References

• 1 Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967-973.
• 2 Burggraf D, Vosko MR, Schubert M. et al. Different therapy options protecting microvasculature after experimental cerebral ischaemia and reperfusion. Thromb Haemost 2010; 103: 891-900.
• 3 Higashida RT, Furlan AJ, Roberts H. et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003; 34: e109-137.
• 4 Kim EY, Lee SK, Kim DJ. et al. Detection of thrombus in acute ischemic stroke: value of thin-section noncontrast-computed tomography. Stroke 2005; 36: 2745-2747.
• 5 Kim EY, Yoo E, Choi HY. et al. Thrombus volume comparison between patients with and without hyperattenuated artery sign on CT. AJNR Am J Neuroradiol 2008; 29: 359-362.
• 6 Kim EY, Heo JH, Lee SK. et al. Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT. Neurology 2006; 67: 1846-1848.
• 7 Riedel CH, Jensen U, Rohr A. et al. Assessment of thrombus in acute middle cerebral artery occlusion using thin-slice nonenhanced Computed Tomography reconstructions. Stroke 2010; 41: 1659-1664.
• 8 Riedel CH, Zimmermann P, Jensen-Kondering U. et al. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011; 42: 1775-1777.
• 9 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581-1587.
• 10 Hacke W, Kaste M, Fieschi C. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. J Am Med Assoc 1995; 274: 1017-1025.
• 11 Nam HS, Lee KY, Han SW. et al. Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients. J Neurol Sci 2009; 281: 69-73.
• 12 Lee K Y, Kim DI, Kim SH. et al. Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke. AJNR Am J Neuroradiol 2004; 25: 1470-1475.
• 13 Heo JH, Lee KY, Kim SH. et al. Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology 2003; 60: 1684-1687.
• 14 Gacs G, Fox A, Barnett H. et al. CT visualization of intracranial arterial thromboembolism. Stroke 1983; 14: 756-762.
• 15 Tomsick T, Brott T, Chambers A. et al. Hyperdense middle cerebral artery sign on CT: efficacy in detecting middle cerebral artery thrombosis. AJNR Am J Neuroradiol 1990; 11: 473-477.
• 16 Chesebro JH, Knatterud G, Roberts R. et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-154.
• 17 Rosenthal ES, Schwamm LH, Roccatagliata L. et al. Role of recanalization in acute stroke outcome: rationale for a CT angiogram-based ”;benefit of recanalization“ model. AJNR Am J Neuroradiol 2008; 29: 1471-1475.
• 18 Brott T, Haley Jr E, Levy D. et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640.
• 19 Haley Jr E, Levy D, Brott T. et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645.
• 20 Yamaguchi T, Mori E, Minematsu K. et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810-1815.
• 21 Nakagawara J, Minematsu K, Okada Y. et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984-1989.
• 22 Mori E, Minematsu K, Nakagawara J. et al. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41: 461-465.
• 23 Chao A-C, Hsu H-Y, Chung C-P. et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke 2010; 41: 885-890.
• 24 Barreto AD, Albright KC, Hallevi H. et al. Thrombus burden is associated with clinical outcome after intra-arterial therapy for acute ischemic stroke. Stroke 2008; 39: 3231-3235.
• 25 Breuer L, Nowe T, Huttner HB. et al. Weight approximation in stroke before thrombolysis: the WAIST-Study: a prospective observational ”dose-finding“ study. Stroke 2010; 41: 2867-2871.
• 26 Lou M, Selim M. Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients?. Cerebrovasc Dis 2009; 27: 84-90.
• 27 Alexandrov AV, Tsivgoulis G. Body weight, not thrombus-burden tissue plasminogen activator dosing: but still. Stroke 2010; 41: 2723-2724.
• 28 Koster RW, van Stralen R, McNeill AJ. et al. A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters. Eur Heart J 1990; 11: 730-739.
• 29 Linfante I, Llinas RH, Selim M. et al. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke 2002; 33: 2066-2071.
• 30 Bhatia R, Hill MD, Shobha N. et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010; 41: 2254-2258.
• 31 del Zoppo GJ, Poeck K, Pessin MS. et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86.
• 32 Lee K Y, Han SW, Kim SH. et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke 2007; 38: 192-193.
• 33 Arnold M, Nedeltchev K, Brekenfeld C. et al. Outcome of acute stroke patients without visible occlusion on early arteriography. Stroke 2004; 35: 1135-1138.
• 34 Gurewich V. Fibrinolysis: an unfinished agenda. Blood Coagul Fibrinolysis 2000; 11: 401-408.
• 35 Lee JA, Croucher DR, Ranson M. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes. Thromb Haemost 2010; 104: 1133-1142.
• 36 Szabo S, Etzel D, Ehlers R. et al. Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis. Drugs Exp Clin Res 2004; 30: 47-54.
• 37 Siller-Matula JM, Schwammeis M, Blann A. et al. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost 2011; 106: 1020-1033.
• 38 Schror K, Bretschneider E, Fischer K. et al. Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins. Thromb Haemost 2010; 103: 884-890.
• 39 Becker RC. Reocclusion following successful thrombolysis. Emerging concepts. Cardiology 1993; 82: 265-273.
• 40 Kharitonova T, Thorén M, Ahmed N. et al. Disappearing hyperdense middle cerebralartery sign in is chaemics troke patients treated with intravenous thrombolysis: clinical course and prognostic significance. J Neurol Neurosurg Psychiatry 2009; 80: 273-278.